NCT05438836Recruiting
Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer
ROAR-A: Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer
Source: ClinicalTrials.gov · Last updated 25 Sept 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
A single-arm, prospective, Phase II, single-center clinical trial that will investigate if daily online adaptive radiotherapy for anal cancer will significantly reduce early treatment-related GI toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 205 (estimated)
- First submitted
- 27 Jun 2022
- Start date
- 1 Jan 2022
- Primary completion date
- 1 Jan 2026
- Lead sponsor
- Herlev Hospital
- NCT number
- NCT05438836
What you commit to
- Study type: Observational
- Planned participants: 205
- From 1 Jan 2022 to the primary completion date, 1 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other malignant disease within the past 5 years (excluding basal cell carcinoma)
Who the study is looking for
- Biopsy-verified anal cancer
- Eligible for curative intended radiotherapy
- Written and oral consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oncology dept, Herlev and Gentofte Hospital Coordinator of this site? Confirm its status | Herlev | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.